Slide 1: Myriad Genetics Fiscal First-Quarter 2017 Earnings Call
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or res
Slide 3: First Quarter Fiscal Year 2017 Financial Results
First Quarter Fiscal Year 2017 Financial Results 1Q17 Actual Results 1Q17 Actual Results (Excluding Assurex) Guidance Revenue $177.5M $170.3 $168 - $170 million Adjusted EPS $0.23 $0.25 $0.25 - $0.27 GAAP EPS ($0.02) $0.00* $0.14 - $0.16 * Based on higher than anticipated closing costs in the quarte
Slide 4: Key Accomplishments in 1Q17
Key Accomplishments in 1Q17 Area Accomplishment Market Expansion and Leadership in Hereditary Cancer Normalized trends by end of quarter Signed physician networks agreements representing 70% of community oncology 65% of revenue under long term contract; in network with 95% of plans Diversifying the
Slide 5: Fiscal First-Quarter 2017 Revenue By Product
Fiscal First-Quarter 2017 Revenue By Product Product 1Q17 1Q16 YoY Growth Hereditary Cancer $139.3 $156.7 (11%) Vectra DA $11.6 $11.4 2% Prolaris $2.9 $0.7 314% GeneSight $7.2* $0.0 NM EndoPredict $1.7 $0.8 113% Other $2.4 $2.3 4% Total Molecular Diagnostic Revenue $165.1 $171.9 (4%) Pharmaceutical
Slide 6: Fiscal First-Quarter Financial Results
Fiscal First-Quarter Financial Results 1Q17 1Q16 YoY Growth Total Revenue $177.5 $183.5 (3%) Gross Profit $137.5 $147.0 (7%) Gross Margin 77.5% 80.1% NA Operating Income $6.2 $43.3 (82%) Adjusted Operating Income $21.6 $46.5 (54%) Adjusted Operating Margin 12.2% 25.3% NA Net Income ($1.2) $30.3 NM D
Slide 7: 2Q17 and FY17 Financial Guidance
2Q17 and FY17 Financial Guidance Metric Fiscal Second-Quarter 2017 Fiscal Year 2017 Revenue $188 to $190 million $740 to $760 million Diluted EPS $0.06 to $0.08 $0.34 to $0.44 Adjusted EPS $0.23 to $0.25 $1.00 to $1.10 For additional information on GAAP to non-GAAP reconciliation see: https://www.my
Slide 8: Review of Guidance Assumptions for FY17
Review of Guidance Assumptions for FY17 Potential Downsides Hereditary cancer out of network decisions Base Case Hereditary cancer decrease consistent with Q4 FY16 YoY decline No incremental payer coverage for Vectra DA, GeneSight, Prolaris or EndoPredict No revenue from myPath, myPlan Lung Cancer o
Slide 9: Value Proposition
Value Proposition Allows identification of patients with high predisposition to cancer where relatively inexpensive preventive measures can be taken to lower risk and reduce future healthcare costs Shown to lower prescription drug costs and healthcare utilization with year one cost savings of ≈$2,60
Slide 10: Changing the Narrative on Our Four Most Important New Tests
Changing the Narrative on Our Four Most Important New Tests $300M in incremental revenue if fully reimbursed 1,200 patient clinical utility study near completion Payer demonstration projects Prospective clinical utility study currently enrolling Three demonstration projects with major payers on redu
Slide 11: Key Studies at American College of Rheumatology Meeting
Key Studies at American College of Rheumatology Meeting Study Using Vectra DA Score to Predict Flare and Sustained Remission (Hirata et al.) Vectra DA Score and Prediction of Radiographic Progression (Brahe et al.) Correlation Between Vectra Score and Myocardial Infarction and Infection (Curtis et a
Slide 12: myChoice HRD Discriminating Power More Important in Future Studies
myChoice HRD Discriminating Power More Important in Future Studies Mkt. Size (in bil.) 35,000 50,000 500,000 450,000 100,000 100,000 myChoice HRD positive patients myChoice HRD negative patients
Slide 13: Pivotal Clinical Study Results in Next Months
10 Pivotal Clinical Study Results in Next 18 Months Indication Number of Studies First Data Expected Total Patients HER2- metastatic breast cancer 4 Mar. 2017 160,000 Neoadjuvant TNBC 2 Mar. 2017 70,000 Other ovarian 3 Mar. 2017 50,000 Pancreatic 1 Dec. 2017 100,000 Total 380,000
Slide 14: Launched Customizable Expanded myRisk Panel
Launched Customizable Expanded myRisk Panel Gene additions added to NCCN Guidelines in June 2016 GREMM1 POLE POLD1 25 Current myRisk genes NBN 1. Updating gene content to provide better care 2. Offering customizable format for customers
Slide 15: Myriad Now Preferred Provider With Largest Oncology Physician Networks
Myriad Now Preferred Provider With Largest Oncology Physician Networks 70% of U.S. Community Oncology Practices Preferred Provider
Slide 16: Market Expansion Opportunity in Hereditary Cancer Exceeds $1B Annually
Market Expansion Opportunity in Hereditary Cancer Exceeds $1B Annually Indication Added Market Potential Guidelines Contracting Colon Cancer @ 5% Mutation Risk +$100M 55% All Endometrial Cancer +$150M 55% Breast Cancer <60 years +$150M FY17 FY18 All Pancreatic Cancer +$125M Partial FY18 Prostate Can
Slide 17: EndoPredict Grows 113% YoY; Reimbursement Expanding
EndoPredict Grows 113% YoY; Reimbursement Expanding 113% Growth French public health care system funding beginning in 1H CY16 covering all patients German national reimbursement (GBA) covering in country testing in authorized major centers Submitting to U.K. NICE and Health Canada by end of CY16 U.S
Slide 18: Third Clinical Validation Presented at ASDP; myPath Melanoma
Third Clinical Validation Presented at ASDP; Dossier Ready for Submission Upon Publication myPath Melanoma Diagnostic Accuracy myPath Melanoma Diagnostic Accuracy myPath Melanoma Clinical Utility n=437 patients n=736 patients n=218 patients n=182 patients
Slide 19: Delivering on >$25 Billion Pipeline Opportunity
Delivering on >$25 Billion Pipeline Opportunity Stage 1 Stage 2 Stage 3 Stage 4 BIPOLAR ENDOMETRIOISIS PSORIATIC ARTHRITIS RENAL CANCER * * * * * * * * * Currently marketed Oncology Preventive Care Urology Autoimmune Dermatology Neuroscience Adoption Reimbursement Validation Discovery